| dbo:abstract
|
- Henri A. Termeer (February 28, 1946 – May 12, 2017) was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry. He was an "advocate for the Massachusetts biotech industry." "To generate revenues to fund the research, Termeer entered into a number of side ventures including a chemical supplies business, a genetic counseling." Termeer was named as one of the top fifty leaders of thought in orphan drugs and rare diseases in a list published by Terrapin for the World Orphan Drug Congress which included "eminent personalities that have advanced rare disease research." Henri was a biotech pioneer long before anyone knew what biotechs were. He founded Genzyme which is often said to have kick started today's orphan drug biotech M&A frenzy. Henri is definitely a mover/shaker in the biotech world and in the orphan drug space. He will always be known as the guy who figured out how to build a great business by making drugs for rare diseases. An inspiration and pioneer, many of his protégés have since moved on to lead other successful companies in the rare disease and biotech space thanks to his influence." — World Orphan Drug Congress 2013 (en)
|
| dbo:almaMater
| |
| dbo:birthDate
| |
| dbo:birthPlace
| |
| dbo:birthYear
| |
| dbo:board
| |
| dbo:deathDate
| |
| dbo:deathPlace
| |
| dbo:deathYear
| |
| dbo:occupation
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 53872 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:almaMater
| |
| dbp:birthDate
| |
| dbp:birthPlace
| |
| dbp:boards
| |
| dbp:caption
| |
| dbp:children
| |
| dbp:deathDate
| |
| dbp:deathPlace
|
- Marblehead, Massachusetts, U.S. (en)
|
| dbp:occupation
|
- Executive (en)
- Biotechnology entrepreneur (en)
|
| dbp:parents
| |
| dbp:spouse
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| schema:sameAs
| |
| rdf:type
| |
| rdfs:comment
|
- Henri A. Termeer (February 28, 1946 – May 12, 2017) was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corpor (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
